^{Last updated: 7 September 2022. Source: Vaccines producers and ECDC data.}

The European Commission has been negotiating intensely to build a diversified portfolio of vaccines for EU citizens at fair prices. Contracts have been concluded with 8 promising vaccine developers, securing a portfolio of up to 4.2 billion doses.

Deliveries of vaccine doses to European Union countries have increased steadily since December 2020. Vaccination has gathered pace across the European Union.

By the end of 2021, roughly 80 % of the EU’s adult population has received primary vaccination (one or two doses) against COVID-19. Meanwhile, the Commission has negotiated three additional contracts with pharmaceutical companies to secure more COVID-19 vaccines – for young people, for the EU’s international partners, for booster shots and to guard against new variants. In September 2022, it authorised two adapted booster vaccines.

Effective and broad vaccination is the best strategy to overcome the pandemic. Based on current evidence, all vaccines authorised in the EU are highly protective against hospitalisation, severe disease and death, with an effectiveness in the general population of over 80%.

There is a clear link between the level of vaccination and hospitalisation and death rates: the higher the vaccination rate, the lower the risk of being hospitalised or dying.

Increasing vaccination rates of all eligible groups, particularly of the elderly, the vulnerable and healthcare workers across the EU, therefore remains the first priority to control the spread of COVID-19.

Evidence shows booster doses offer a significant increase in protection against infection and severe diseases. In July 2022, in view of the resurgence of COVID-19 infections, the European Centre for Disease Prevention and Control and the European Medicines Agency have recommended a second booster dose of COVID-19 vaccines for people between 60 and 79 years old and people with medical conditions putting them at high risk of severe disease.

To secure enough doses, the Commission has also worked closely with the industry to step up vaccine manufacturing capacity in the EU. At the same time, the Commission has started work to anticipate and tackle new variants of the virus and to rapidly develop and produce vaccines effective against those variants on a large-scale.

This is why the European Commission has launched HERA, the European Health Emergency preparedness and Response Authority. HERA will anticipate threats and potential health crises, through intelligence gathering and building the necessary response capacities to enable rapid response to health emergencies. 

The Commission has so far given six conditional marketing authorisations for the vaccines developed by BioNTech and Pfizer, Moderna, AstraZeneca, Janssen Pharmaceutica NV, Novavax and Valneva respectively, following the European Medicines Agency’s (EMA) positive assessment of their safety and efficacy. Several other vaccines are at different stages of assessment by the EMA.

^{*option to purchase 900 million doses, **option to purchase 100 million doses}

The European Medicines Agency publishes safety updates for the COVID-19 vaccines authorised in the EU. EMA releases a monthly update for each authorised COVID-19 vaccine.

The safety updates summarise the data that have become available since the vaccine's authorisation. They also indicate whether any safety information requires further investigation.

For more information, visit the EMA webpage.

Disinformation on the coronavirus is thriving. It is important that you get updated information from authoritative sources only. We suggest that you follow the advice of your public health authorities, and the websites of relevant EU and international organisations: the European Centre for Disease Control (ECDC ) and the World Health Organization (WHO).

You can also help by not sharing unverified information that comes from dubious sources.

Fighting disinformation

With the EU Vaccines Strategy, the EU is supporting efforts to accelerate the development and availability of safe and effective vaccines in a timeframe of less than one year for most vaccines.

The Commission entered into advanced purchase agreements with individual vaccine producers on behalf of the Member States, and secured more than 4.2 billion doses of vaccines for European citizens and for countries around the world where vaccines are less available.